

**Theravance**Facsimile Cover Sheet

**To:** Examiner Garcia  
**Company:** USPTO  
**Telephone:** 703-308-0065  
**Fax:** 703-746-5246

**From:** Jeff Hagenah  
**Company:** Theravance, Inc.  
(formerly Advanced Medicine, Inc.)  
**Telephone:** 650-808-6406  
**Fax:** 650-808-6078  
**Date:** April 11, 2002  
**# of pages:** 13  
(including this page)

If there are any problems in receiving this transmission, please call (650) 808-6000

**Comments: Examiner Garcia:**

Attached is a copy of the response filed on March 18, 2002 for U.S. Serial No. 09/457,926. I would like to discuss this response with you during the interview scheduled for April 18<sup>th</sup>, at 10:00 am. Thanks.

Jeff

**Notice of Confidentiality**

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

---

PRIVILEGED AND CONFIDENTIAL

---

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 827-8690

Received from < 650 808 6078 > at 4/11/02 12:11:11 PM [Eastern Daylight Time]

*Filed  
by official  
FAX  
3/18/02*

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. (703) 872-9306, on the date shown below:

Dated: 3-18-02By: Jeffrey A. Hagenah

Reg. No. 35,175

Patent

Attorney's Docket No. 032367-449 (AMI-061-R2)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )

Burton CHRISTENSEN, et al. )

Application No.: 09/457,926 )

Filed: December 8, 1999 )

For: NOVEL ANTI-BACTERIAL AGENTS )

Group Art Unit: 1627

Examiner: M. Garcia

24/C  
18/PPS  
4-19-02**REPLY AND AMENDEMNT PURSUANT TO 37 C.F.R. §1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Reply and Amendment is being filed in response to the Office Action (Paper No. 22) mailed on December 18, 2001, for the above-identified patent application. In response to the Office Action, entry of the following amendments is respectfully requested.

**In the Claims:**Please amend Claim 50 as follows:   L  

50. (Amended) The compound according to Claim 41, wherein "L" is a vancomycin moiety which is attached to the linker at the amino terminus of the vancomycin moiety.

C1